Syntorr LP v Arthrex (CoA, UPC_CoA_890/2025, 18 February 2026)
| Date | 18 February 2026 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Application For Costs |
| Case number(s) | UPC_CoA_890/2025 |
| Registry reference | UPC-COA-0000890/2025 |
| Parties | Syntorr LP v. Arthrex Inc., Arthrex GmbH, Arthrex Distribution Hub EMEA B.V. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 18 February 2026 (UPC_CoA_890/2025), the Court of Appeal, on discretionary review, set aside the Munich Local Division’s orders requiring Syntorr, claimant in an infringement action on EP 2 670 898 against three Arthrex companies, to provide security for costs of EUR 2,000,000. It dismissed the request for security and ordered the release of the bank guarantee provided. The decision matters for funded claimants: litigation insurance with an anti-avoidance endorsement may remove any legitimate concern that costs will not be recovered.
Question
Must an insurance policy covering the defendant’s costs, made non-cancellable and non-voidable by a specific endorsement, be taken into account when assessing the claimant’s financial position under Art. 69(4) UPCA and Rule 158.1 RoP?
Decision
Security is meant to protect a defendant against a claimant without sufficient means (paragraph 17), the court asks whether the claimant’s financial position gives rise to a legitimate and real concern that a costs order may not be recoverable, or only in an unduly burdensome way (paragraph 19), the burden of substantiation lying on the applicant (paragraph 20). The insurance policy forms part of that financial position (paragraph 25). Syntorr sufficiently established its validity, with a limit of EUR 4,000,000 (paragraphs 26 to 28), the endorsement makes the policy non-voidable and non-cancellable up to that limit and the defendants can enforce it directly (paragraphs 29 and 30), the payment procedure is straightforward (paragraph 31) and the insurer, established in the Union, is subject to Solvency II (paragraph 34). There was no legitimate concern, so security was not necessary (paragraph 35), and the guarantee was released by analogy with Rule 352.2 RoP (paragraph 37).
Key points for practice
- Insurance covering adverse costs, non-cancellable and directly enforceable by the defendant, may defeat an application for security (paragraphs 25 to 35).
- Whether insurance is itself a permissible form of security under Rule 158.1 RoP remains open (paragraph 36).
Provisions applied
- Agreement on a Unified Patent Court
- Art. 69(4)
- Rules of Procedure
- Rules 158.1, 220.3, 220.4, 333 and 352
- Other provisions
- Directive 2009/138/EC (Solvency II)
- Case law cited
- ICPillar v ARM, Court of Appeal, 16 September 2024, AorticLab v Emboline, Court of Appeal, 20 June 2025, Audi v Network System Technologies, Court of Appeal, 17 September 2024, Volkswagen v Network System Technologies, Court of Appeal, 17 September 2024, Chint v JingAo, Court of Appeal, 9 July 2025, Suinno v Microsoft, Court of Appeal, 12 July 2025, Oerlikon v Bhagat, Court of Appeal, 30 October 2025
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal, Court fees and costs (UPC).
Dhenne Avocats blog: UPC Appeals: What the Numbers Show.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantSyntorr LP2 decisions in the corpusFollow this party
- defendantArthrex Inc.4 decisions in the corpusFollow this party
- defendantArthrex GmbH4 decisions in the corpusFollow this party
- defendantArthrex Distribution Hub EMEA B.V.4 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application For Costs
- Outcome (Dhenne Avocats summary)
- La cour d'appel annule la garantie de 2 000 000 euros imposée à Syntorr, son assurance couvrant les frais adverses, non résiliable et directement invocable, écartant toute crainte légitime de non-recouvrement.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 2 670 898mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Oerlikon Textile v Bhagat Textile Engineers (CoA, 30 October 2025) cited in this record
- Suinno Mobile & AI Licensing v Microsoft (CoA, 12 July 2025) cited in this record
- Chint New Energy v JingAo Solar (CoA, 9 July 2025) cited in this record
- AorticLab v Emboline (CoA, 20 June 2025) cited in this record
- Volkswagen v Network System Technologies (CoA, 17 September 2024) cited in this record
- Audi v Network System Technologies (CoA, 17 September 2024) cited in this record
- In(k)control v Esko-Graphics (CFI, UPC_CFI_871/2026, 16 September 2026, doc. 2) cites this decision
- Biopsafe v Kaltek (CFI, 30 July 2026) cites this decision
- Boa v Shinkyung (CFI, UPC_CFI_996/2025, 1 June 2026) cites this decision
- Boa v Shinkyung (CFI, UPC_CFI_998/2025, 1 June 2026) cites this decision
- Boa Technology v Zuatu Cycling International d.o.o. (CFI, 1 June 2026) cites this decision
- Shenzhen Transsion Holdings v Telefonaktiebolaget LM Ericsson (CFI, UPC_CFI_850/2026, 26 May 2026, doc. 2) cites this decision
- Advanced Standard Communication v XIAOMI (CoA, 19 May 2026) cites this decision
- Establishment Labs v GC Aesthetics Parentco (CFI, 18 March 2026) cites this decision
- La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 13 March 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 670 898 | Mentioned in the analysis (role not qualified) Also mentioned in 1 other decision(s): Syntorr v Arthrex (CFI, ORD_25293/2025, 11 August 2025) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.